RNA Vaccine Boosting CAR-T Cell Solutions

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In the realm of cancer immunotherapy, CART cell therapy has emerged as a breakthrough approach for the treatment of various hematologic malignancies. However, the effectiveness of CAR-T cells in targeting solid tumors has posed significant challenges. To overcome these limitations, companion vaccines for CAR T-cell therapy have been applied for basic immunology to enhance therapeutic efficacy. In these vaccine types, the combination of RNA vaccine serves as a novel strategy to enhance the anti-tumor response of CAR-T cells towards solid tumors.

Advantages of RNA Vaccine for CART Combination Solution

Compared to traditional vaccines, RNA vaccines offer several distinct advantages in the context of CART combination therapy. RNA vaccines provide a versatile platform for delivering the CAR antigen into lymphoid compartments, thereby stimulating the adoptively transferred CAR-T cells effectively. By enabling the presentation of the target antigen on resident antigen-presenting cells, RNA vaccines promote the selective expansion of CAR-T cells and enhance their therapeutic efficacy. Moreover, the inherent flexibility and scalability of RNA vaccine technology make it an ideal candidate for enhancing the functionality and persistence of CAR-T cells in vivo.

Fig.1 Proliferation test of CAR-T cell in resected secondary lymphoid after RNA-LPX intravenous administration.¹

Services for RNA Vaccine Boosting CAR-T Cell Solutions at Creative Biolabs

Creative Biolabs offers a comprehensive range of products and services tailored to the development and optimization of RNA Vaccine Boosting CAR-T Cell Solutions. We provide various products, such as mRNA IVT plasmids, IVT mRNA, and mRNA-LNP formulations, to support the development of the efficient delivery of RNA vaccines targeting specific cancer antigens. At the same time, with a suite of cutting-edge technologies, we are committed to offering a comprehensive range of services to further advance this solution. Our related services include but are not limited to:

Native Antigen-encoded Nanoparticulate RNA Production Service
In Vitro DC Characterization Pulsed with mRNA Liposome
In Vitro CAR-T Cell Functional Analysis with mRNA Liposome Pulsed DCs
In Vivo Native Antigen Validation on Splenic Immune Cell Populations
In Vivo CAR-T Cell Functional Analysis After Intravenous Administration of mRNA-liposome Vaccine

Applications of RNA Vaccine Boosting CAR-T Cell Solutions

The application of RNA vaccine boosting CAR-T cell solutions extends to a diverse range of cancer indications, particularly in the context of solid tumors. By leveraging the synergistic effects of RNA vaccines and CAR-T cells, this innovative approach holds immense potential for overcoming the challenges associated with poor CAR-T cell stimulation and persistence in solid tumor microenvironments. Preclinical studies have demonstrated the effectiveness of enhanced CAR-T cell therapy regimens combined with RNA vaccines in enhancing the tumor-killing activity of CAR-T cells and inducing complete tumor regression in mouse models. These promising results pave the way for the clinical application of RNA vaccine in combination with CAR-T cells, offering new hope for patients with advanced solid tumors.

Fig.2 Detection of maintaining frequency of circulating CAR-T cells within a therapeutic window upon RNA vaccine combination.¹

Our Advantages

Creative Biolabs is committed to combining cutting-edge technologies with a deep understanding of cancer immunotherapy to deliver customized solutions for enhancing CAR-T cell therapy. Please feel free to contact us if you have any requirements related to CART projects.

Reference

Reinhard, Katharina, et al. "An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors." Science 367.6476 (2020): 446-453.